Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:37:50.270Z.
Consensus retrieved: 2026-10-06T13:25:27.564Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:37:50.270Z.
Quote observation: 2026-10-06T16:22:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 00b46e2a658eb37d32f3c4bb775d4183c2cde6b20987a1f72f3e7425ee882fe4
Forward PE Ratio (N/A) = Dated Quote Price ($21.40) / Consensus Forward EPS ($-0.52)
FORWARD PE RATIO
N/A
LifeMD, Inc.
Market Cap
$145.90M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| LifeMD, Inc. (LFMDP) | $145.90M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.19M | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.60M | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $148.43M | N/A |
| Immuneering Corporation (IMRX)vs › | $143.21M | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.70M | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $149.27M | N/A |
| Codexis, Inc. (CDXS)vs › | $150.59M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 6.96 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $21.40, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.52 | $-0.55 – $-0.49 | 1 | n/m |
| 2027-12-31 | $-0.09 | $-0.10 – $-0.09 | 1 | n/m |
| 2028-12-31 | $0.15 | $0.14 – $0.16 | 1 | 140.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
